These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 21729670)

  • 1. Prevalence and prognostic role of triple-negative breast cancer by race: a surveillance study.
    Swede H; Gregorio DI; Tannenbaum SH; Brockmeyer JA; Ambrosone C; Wilson LL; Pensa MA; Gonsalves L; Stevens RG; Runowicz CD
    Clin Breast Cancer; 2011 Oct; 11(5):332-41. PubMed ID: 21729670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early and Locally Advanced Metaplastic Breast Cancer: Presentation and Survival by Receptor Status in Surveillance, Epidemiology, and End Results (SEER) 2010-2014.
    Schroeder MC; Rastogi P; Geyer CE; Miller LD; Thomas A
    Oncologist; 2018 Apr; 23(4):481-488. PubMed ID: 29330212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High incidence and frequency of LOH are associated with aggressive features of high-grade HER2 and triple-negative breast cancers.
    Tokunaga E; Okada S; Yamashita N; Akiyoshi S; Kitao H; Morita M; Kakeji Y; Maehara Y
    Breast Cancer; 2012 Apr; 19(2):161-9. PubMed ID: 21063923
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hormone receptor and HER2 status in patients with breast cancer by races in southeastern Turkey.
    Kuzhan A; Adli M; Eryigit Alkis H; Caglayan D
    J BUON; 2013; 18(3):619-22. PubMed ID: 24065473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is breast cancer from Sub Saharan Africa truly receptor poor? Prevalence of ER/PR/HER2 in breast cancer from Kenya.
    Sayed S; Moloo Z; Wasike R; Bird P; Oigara R; Govender D; Kibera J; Carrara H; Saleh M
    Breast; 2014 Oct; 23(5):591-6. PubMed ID: 25012047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Racial differences in estrogen receptor staining levels and implications for treatment and survival among estrogen receptor positive, HER2-negative invasive breast cancers.
    Purrington KS; Gorski D; Simon MS; Hastert TA; Kim S; Rosati R; Schwartz AG; Ratnam M
    Breast Cancer Res Treat; 2020 May; 181(1):145-154. PubMed ID: 32236827
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of human epidermal growth factor receptor 2 in the survival of women with estrogen and progesterone receptor-negative, invasive breast cancer: the California Cancer Registry, 1999-2004.
    Brown M; Tsodikov A; Bauer KR; Parise CA; Caggiano V
    Cancer; 2008 Feb; 112(4):737-47. PubMed ID: 18189290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A study of high-nuclear-grade breast cancer in Thailand: subclassification and correlation with prognostic factors and immunohistochemical study.
    Chaiwun B; Nakrungsee S; Sukhamwang N; Srisukho S
    Breast Cancer; 2010; 17(1):35-41. PubMed ID: 19789946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Breast cancer as heterogeneous disease: contributing factors and carcinogenesis mechanisms.
    Kravchenko J; Akushevich I; Seewaldt VL; Abernethy AP; Lyerly HK
    Breast Cancer Res Treat; 2011 Jul; 128(2):483-93. PubMed ID: 21225455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Racial Differences in the Use and Outcome of Neoadjuvant Chemotherapy for Breast Cancer: Results From the National Cancer Data Base.
    Killelea BK; Yang VQ; Wang SY; Hayse B; Mougalian S; Horowitz NR; Chagpar AB; Pusztai L; Lannin DR
    J Clin Oncol; 2015 Dec; 33(36):4267-76. PubMed ID: 26598753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Breast cancer receptor status and stage at diagnosis in over 1,200 consecutive public hospital patients in Soweto, South Africa: a case series.
    McCormack VA; Joffe M; van den Berg E; Broeze N; Silva Idos S; Romieu I; Jacobson JS; Neugut AI; Schüz J; Cubasch H
    Breast Cancer Res; 2013; 15(5):R84. PubMed ID: 24041225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reproductive risk factor associations with lobular and ductal carcinoma in the Carolina Breast Cancer Study.
    Williams LA; Nichols HB; Hoadley KA; Tse CK; Geradts J; Bell ME; Perou CM; Love MI; Olshan AF; Troester MA
    Cancer Causes Control; 2018 Jan; 29(1):25-32. PubMed ID: 29124544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinicopathological analyses of triple negative breast cancer using surveillance data from the Registration Committee of the Japanese Breast Cancer Society.
    Iwase H; Kurebayashi J; Tsuda H; Ohta T; Kurosumi M; Miyamoto K; Yamamoto Y; Iwase T
    Breast Cancer; 2010 Apr; 17(2):118-24. PubMed ID: 19466512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status.
    Howlader N; Altekruse SF; Li CI; Chen VW; Clarke CA; Ries LA; Cronin KA
    J Natl Cancer Inst; 2014 Apr; 106(5):. PubMed ID: 24777111
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distribution of molecular breast cancer subtypes among Algerian women and correlation with clinical and tumor characteristics: a population-based study.
    Cherbal F; Gaceb H; Mehemmai C; Saiah I; Bakour R; Rouis AO; Boualga K; Benbrahim W; Mahfouf H
    Breast Dis; 2015; 35(2):95-102. PubMed ID: 25736840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Female breast cancer status according to ER, PR and HER2 expression: a population based analysis.
    Caldarella A; Crocetti E; Bianchi S; Vezzosi V; Urso C; Biancalani M; Zappa M
    Pathol Oncol Res; 2011 Sep; 17(3):753-8. PubMed ID: 21479875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hormone receptor-negative breast cancer: undertreatment of patients over 80.
    Weiss A; Noorbakhsh A; Tokin C; Chang D; Blair SL
    Ann Surg Oncol; 2013 Oct; 20(10):3274-8. PubMed ID: 23838924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of age distribution patterns for different histopathologic types of breast carcinoma.
    Anderson WF; Pfeiffer RM; Dores GM; Sherman ME
    Cancer Epidemiol Biomarkers Prev; 2006 Oct; 15(10):1899-905. PubMed ID: 17035397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hormone receptor status does not affect prognosis in metaplastic breast cancer: a population-based analysis with comparison to infiltrating ductal and lobular carcinomas.
    Paul Wright G; Davis AT; Koehler TJ; Melnik MK; Chung MH
    Ann Surg Oncol; 2014 Oct; 21(11):3497-503. PubMed ID: 24838367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence, mortality and receptor status of breast cancer in African Caribbean women: Data from the cancer registry of Guadeloupe.
    Deloumeaux J; Gaumond S; Bhakkan B; Manip M'Ebobisse N; Lafrance W; Lancelot P; Vacque D; Negesse Y; Diedhiou A; Kadhel P
    Cancer Epidemiol; 2017 Apr; 47():42-47. PubMed ID: 28119121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.